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Introduction
Triple assessment, consisting of clinical evaluation, mammog-
raphy or ultrasound, and fine-needle aspiration (FNA) cytology,
allows precise initial diagnosis of palpable breast masses and
reduces the risk of misdiagnosis.1 FNA cytology is usually
performed on palpable breast masses, especially in cases sus-
pected of malignancy, and positive cytology is considered
sufficient evidence for a diagnosis of breast cancer. Such cases
can then be treated using mastectomy or breast-conserving
surgery without the need for a time-consuming tumour biopsy.
However, because there are false-negative cases, attribut-
able to a variety of factors besides technical failure, the diag-
nostic accuracy of FNA biopsy for breast cancer is only around
95%. The treatment of FNA cytology-negative patients who are
otherwise suspected of having malignant breast cancer based
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on physical and/or breast imaging findings, or in whom such
findings are equivocal, presents a dilemma. Since several stud-
ies have shown that delay in the diagnosis of breast cancer
reduces survival,2,3 early definitive diagnosis of breast masses
is important in FNA cytology-negative cases.
Core needle biopsy (CNB), on the other hand, is thought to
provide a more exact diagnosis of breast tumours,4 especially
non-palpable breast tumours. However, CNB is not widely
used in some medical centres, especially in Asian countries,
because it takes more time, often necessitates anaesthesia, and
requires many staff members who are familiar with certain
techniques. As a result, it is sometimes difficult to decide on
the next step, that is, whether to perform a CNB, a lumpectomy
or more extensive surgery.
In this study, we assessed the clinical usefulness of
FNA biopsy of breast tumours in the preoperative diagnosis
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of breast cancer and carefully reviewed the FNA cytology-
negative cases.
Materials and methods
The subjects in the present study were among 94 patients who
underwent FNA cytology of palpable breast masses in the First
Department of Surgery, Mie University Hospital, between
January 1995 and December 2002. Their ages ranged from 25
to 78 years (mean, 51 years). Informed consent was obtained
from every patient before cytology. There were no major com-
plications or significant complaints of pain. FNA cytology was
followed by lumpectomy or mastectomy, and a histological
diagnosis was made in every patient.
The technique of FNA has been described previously.5
Briefly, aspirates were obtained with a 22 gauge needle and a
20 mL syringe, and the needle was guided by ultrasound
(US) whenever the tumour was smaller than 2 cm. At least two
aspirates were collected each time FNA was performed, and
direct smears were prepared for cytology. Alcohol-fixed smears
were stained with Papanicolaou stain. Unsatisfactory smears
were excluded and repeat FNA cytology was performed shortly
thereafter. The diagnostic FNA cytology classification was:
class I, benign; class II, probably benign; class III, equivocal;
class IV, probably malignant; and class V, malignant. The
definition of “cytological malignancy”, or possible malig-
nancy, comprised classes III, IV and V. The sensitivity, specificity
and accuracy of FNA biopsy for the diagnosis of malignancy
were calculated.
The physical examination findings and the ultrasono-
graphy, mammography and magnetic resonance imaging
(MRI) findings were reviewed in FNA cytology-negative cases
in an attempt to identify clinical and radiological findings that
were helpful in managing FNA cytology-negative cases. Le-
sions were suspected of being malignant whenever any of the
following findings were present: skin dimpling on physical
examination, irregular-shaped mass with or without posterior
echo attenuation on ultrasonography, category 3 or more on
mammography, and early enhancement on a dynamic MRI
study.
Statistical analysis
Comparisons between the two groups were made using the
Chi-squared test for discrete variables. Statistical analysis was
performed using SPSS version 10.0 (SPSS Inc, Chicago, IL,
USA) and p values less than 0.05 were considered statistically
significant.
Results
Accuracy of FNA biopsy
The relationship between FNA cytology and the histopatho-
logical findings is shown in Table 1. Evaluation of the accuracy
of FNA biopsy yielded a sensitivity of 91% (72/79), specificity
of 93% (14/15) and accuracy of 91% (86/94). FNA biopsy had
a positive predictive value of 99% (72/73) and a negative
predictive value of 67% (14/21). Seven false-negative cases
(class I, 1; class II, 6) and one false-positive case (class IV, 1) were
identified.
Final histopathological diagnosis according to FNA
cytology findings
Table 2 shows the final histopathological diagnoses of the
breast masses according to the preoperative cytology class.
The seven false-negative biopsy specimens were obtained from
three cases of scirrhous carcinoma, three cases of papillotubular
carcinoma and one case of mucinous carcinoma. Of the 15
benign cases, nine were fibroadenomas, five were fibrocystic
disease and one was a cyst. Cytology was class IV in one of the
benign cases, but excisional biopsy revealed fibrocystic disease.
Triple assessment of breast masses in FNA
cytology-negative cases
Table 3 shows the background and results of imaging studies
in the 21 FNA cytology-negative cases. Mean age and mean
tumour diameter were not significantly different. The physi-
cal findings suggested malignancy in six malignant and nine
benign cases, while US findings suggested malignancy in six
malignant and seven benign cases. In contrast, the proportion
of cases in which mammography findings were suggestive of
malignancy was much higher among malignant cases than
benign cases (5/7 vs 5/14). Moreover, although the number of
cases was small, MRI showed evidence of malignancy in all
Table 1. Fine-needle aspiration cytology and histological
findings in the diagnosis of breast masses
Malignant Benign Total
(n = 79)  (n = 15)  (n = 94)
Class I 11 12 13
Class II 16 12 18
Class III 17 10 17
Class IV 13 11 14
Class V 52 10 52
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Table 2. Histological diagnoses of breast masses according to cytology findings
Malignant (n = 79) Benign (n = 15)
Scirrhous Papillotubular Solid-tubular Others Fibroadenoma Fibrocystic disease Cyst
Class I 11 10 10 0 1 1 0
Class II 12 13 10 11* 8 3 1
Class III 13 11 13 0 0 0 0
Class IV 14 16 13 0 0 1 0
Class V 19 17 13  3† 0 0 0
Total 29 27 19 4 9 5 1
*Mucinous; †mucinous, medullary and pagetoid.
Table 3. Triple assessment of breast masses in fine-needle aspiration (FNA) cytology-negative cases
Histological Mean age Mean size
First FNA
Physical Malignant findings
diagnosis (yr)  (cm) examination US Mammogram MRI
Malignant (n = 7)* 52 2.0 Class I (n = 1), class II (n = 6) 6/7 6/7 5/7 3/3
Benign (n = 14)† 55 2.3 Class I (n = 2), class II (n = 12) 9/14 7/14 5/14 0/2
*Invasive ductal carcinoma (n = 6) and mucinous carcinoma (n = 1); †fibroadenoma (n = 9), mastopathy (n = 4) and cyst (n = 1).
US = ultrasound; MRI = magnetic resonance imaging.
Table 4. Clinicopathological characteristic of fine-needle aspiration (FNA) biopsy false-negative cases
Case Age (yr) Size (cm) First FNA Method of definitive diagnosis Operation Histological diagnosis Stage
  1 36 4.0 Class I Repeat FNA (Class V) Brt + Mn + Ax Scirrhous carcinoma II
  2 71 3.5 Class II Wide excision Bp Papillotubular carcinoma* I
  3 46 2.5 Class II Wide excision Bp + Ax Mucinous carcinoma I
  4 51 2.0 Class II Repeat FNA (Class V) Brt + Ax Scirrhous carcinoma I
  5 53 2.0 Class II Lumpectomy Brt + Ax Papillotubular carcinoma II
  6 51 1.5 Class II Lumpectomy Bp + Ax Papillotubular carcinoma* I
  7 57 1.0 Class II Lumpectomy Bp + Ax Scirrhous carcinoma* I
*Including cystic change. Brt = mastectomy; Mn = resection of minor pectoral muscle; Ax = dissection of axillary lymph node; Bp = partial
mastectomy.
three malignant cases, while no findings of malignancy were
observed in the benign cases.
FNA cytology-false-negative cases
The clinicopathological characteristics of the seven false-
negative cases are shown in Table 4. All seven patients were re-
examined by FNA biopsy. Cases 1 and 4 were diagnosed as
breast cancer (class V), while class II or III cytology findings
were demonstrated in the other five cases. Lumpectomy
(tumour resection with a minimal cancer-free margin) or wide
excision (tumour resection with a cancer-free margin of at
least 1 cm) was performed within 1 week because of strong
suspicion of malignancy based on the physical and imaging
findings.
Class III cases
The FNA cytology was class III in seven cases, and repeat FNA
biopsy was performed within a week in all cases. Based on the
second FNA cytology, six cases were diagnosed as breast cancer
(class V, 1; class IV, 5). The other case was again diagnosed as
class III, and lumpectomy was performed 1 week later because
the tumour was 1.5 cm in diameter. The histological diagnosis
was scirrhous carcinoma and breast-conserving surgery was
carried out.
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Discussion
The first step in the management of every patient presenting
with a palpable breast mass after clinical evaluation is assess-
ment consisting of clinical evaluation, mammography or
ultrasound, and FNA cytology. These allow precise initial
diagnosis of palpable breast tumours and reduce the risk of
misdiagnosis.1 FNA biopsy can be performed in an outpatient
department because there are no absolute contraindications
and no major complications associated with the procedure.
FNA of the breast is a safe, reliable and minimally invasive
biopsy technique. This method has been found to be very
accurate for diagnosis of breast cancer in our hospital, with a
sensitivity of 91%, specificity of 93%, accuracy of 91%, and a
positive predictive value of 99%. However, with a negative
predictive value of only 67%, we focused on FNA cytology-
negative cases and how to treat them. Most authors have
reported sensitivities, specificities and accuracies of more than
90% (Table 5).6–8 However, negative predictive values were
worse in all reports.
False-negative cases invariably occur and lessen the useful-
ness of FNA cytology. Several studies have examined the ap-
proach to FNA-negative cases. Tsukamoto et al pointed out
that diagnostic accuracy varies significantly with the skill of
the cytologist and/or aspirator.9 Jenner et al indicated that
triple assessment, consisting of clinical examination, radio-
graphic assessment by mammography and cytological assess-
ment using FNA cytology, is not sensitive enough to detect
every breast cancer and that a high incidence of diagnostic
delay is therefore inevitable with the biopsy and cytodiagnostic
techniques currently available.10 To increase the accuracy of
FNA biopsy, cytologists and aspirators should review the
results of every FNA biopsy to improve their skill.
Recent reports describe various advanced biopsy devices
and methods of diagnosis designed to allow earlier and more
accurate diagnosis of breast cancer. Schwartzberg et al indi-
cated that advanced breast biopsy instrumentation, including
stereotactic and ultrasonography-guided automated 14-gauge
needle core biopsy, stereotactic vacuum-assisted core biopsy
and needle localization excisional breast biopsy, are safe, reli-
able and minimally invasive, making these techniques very
useful, especially in patients with abnormal mammographic
findings but no palpable lesions.11 In addition, Tsukamoto
and coworkers reported that the diagnostic accuracy of fluo-
rescence in situ hybridization (FISH) of FNA samples is com-
parable to that of conventional cytology and that FISH is
useful in making a definitive diagnosis of malignancy in pa-
tients with indeterminate cytology findings.9
In our institution, stereotactic core biopsy has been used to
diagnose some breast masses since 2001. All were diagnosed as
breast cancer and all results were confirmed. However, in any
institution, it takes time to become familiar with core biopsy
techniques before this can be used with certainty as a reliable
method of diagnosis.
There is a consensus that a delay of more than 6 months in
the diagnosis of breast cancer is associated with a lower sur-
vival rate.12 A recent systematic review of the literature at-
tempted to correct for lead-time bias.13 The authors suggested
that a delay of more than 3 months may significantly reduce
survival time. The problem, therefore, seems to be how to deal
with negative cases according to FNA biopsy results. Apantaku
suggests that FNA biopsy should be used as the initial diagnos-
tic test, and that if needle cytology and imaging studies are
negative, the mass should be closely monitored by a repeat
physical examination in 2 months and repeat imaging in 6
months.14 Lumpectomy might be recommended instead of
FNA cytology when a mass is suspected of being malignant
clinically.14 Accordingly, in the present study, we reviewed the
21 FNA cytology-negative cases on the basis that evidence of
the presence or absence of malignancy was frequently detected
on physical examination and imaging studies. Physical exami-
nations and US studies were poor means of differentiating
between benign and malignant lesions, whereas evidence of
malignancy was frequently detected by mammography and
MRI. The ability of MRI to differentiate between benign and
malignant disease was particularly high. The International
Table 5. Reports showing fine-needle aspiration results
Report Sensitivity, % Specificity, % Accuracy, % Positive predictive value, % Negative predictive value, %
Ayata et al6 99 99 99 100 96
Ariga et al7 98 98 98 99 91
Chaiwun et al8 84 99 91 99 84
Present study 91 93 91 99 67
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Breast Cancer Consensus Conference concluded that MRI is a
promising technology with the potential to solve many breast
cancer management problems and that it is helpful in pre-
operative evaluation of the extent of local tumours.15 MRI
has also recently been found to be useful in detecting intraduc-
tal spread and estimating the extent of breast cancer.16
The following protocol is used in our clinic to diagnose
and treat FNA cytology-negative cases (class I or II) in which a
malignant breast tumour is suspected based on physical and
imaging findings, especially from MRI (Figure). If FNA is
negative but US or mammography indicates malignancy, we
perform MRI. Recently, using MRI, most cases have been
diagnosed as various histological types, such as solid-tubular,
mucinous, papillotubular, scirrhous carcinoma or papillary
and cystic lesions. If a solid-tubular or mucinous carcinoma is
suspected from MRI, we perform repeat FNA, because these
types are thought to be easy to diagnose by FNA, and most
false-negatives are caused by technical failure. If papillotubular
carcinoma or scirrhous carcinoma is suspected from MRI, we
perform CNB, because these types are not as easily diagnosed
by FNA as solid-tubular or mucinous carcinoma. If a papillary
or cystic lesion is suspected from MRI, we perform excisional
biopsy because these types may be difficult to diagnose pre-
cisely even by CNB.
The handling of class III cases has been controversial
because class III means suspicion of malignancy. We perform
MRI in most class III cases and follow the protocol shown in
the Figure.
We conclude that aspiration cytology is an accurate pre-
operative diagnostic procedure for the evaluation of breast
masses, and that whenever there is clinical or radiological
suspicion of malignancy, in negative FNA cases based on MRI
findings, repeat FNA, CNB or excisional biopsy needs to be
performed.
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Figure. Algorithm of approach to fine-needle aspiration (FNA)
cytology-negative cases. US = ultrasound; MRI = magnetic reso-
nance imaging; CNB = core needle biopsy.
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